Enclomiphene Citrate Pediatric (Under 12) Dosing: What Clinicians and Parents Need to Know

What Is Enclomiphene Citrate and Why Does Pediatric Dosing Matter?

Enclomiphene citrate is the trans-isomer of clomiphene citrate, separated from its cis-isomer (zuclomiphene) to retain the hypothalamic estrogen-receptor-blocking effect while reducing the peripheral estrogenic side effects associated with the racemic mixture. In adult men with secondary hypogonadism, enclomiphene raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulates endogenous testosterone production while preserving spermatogenesis. Kim et al. (BJU Int 2016, N=71) demonstrated that enclomiphene 12.5 mg and 25 mg daily restored serum testosterone to normal range in men with secondary hypogonadism while maintaining sperm concentrations superior to those seen with topical testosterone [1].

The question of dosing in children under 12 arises in specific clinical contexts: boys with hypothalamic or pituitary pathology causing central hypogonadotropic hypogonadism, adolescents with Prader-Willi syndrome, and, less commonly, cases of delayed puberty where a clinician is considering off-label stimulation of the HPG axis. These are not minor edge cases for the families involved, and the absence of a clear dosing framework creates real risk.

No pediatric pharmacokinetic study has been conducted for enclomiphene. No phase 1, phase 2, or phase 3 trial has enrolled children under 12. The FDA has not issued a pediatric written request or a required pediatric assessment under the Best Pharmaceuticals for Children Act (BPCA) or the Pediatric Research Equity Act (PREA) for enclomiphene, in part because the drug has never achieved NDA approval as a finished product [2].

Understanding what the evidence does and does not support is essential before any prescribing decision is made.

FDA Approval Status and Regulatory Context for Enclomiphene in Children

Enclomiphene citrate has no FDA-approved finished drug product for any age group. The regulatory history matters here.

Repros Therapeutics pursued NDA approval for enclomiphene (brand name Androxal) for secondary hypogonadism in adult men. The FDA issued a Complete Response Letter in 2013 citing cardiovascular safety concerns, and the program was discontinued [3]. Because no NDA was approved, PREA never applied. That means the manufacturer was never required to conduct pediatric studies, and the FDA never issued formal guidance on pediatric dosing, contraindications, or safety warnings specific to children.

Enclomiphene available today is compounded by 503A pharmacies (for individual patient prescriptions) or 503B outsourcing facilities. The FDA's guidance on bulk drug substances for compounding does not include enclomiphene on the 503B list of nominated bulk substances that have been evaluated and approved for that use [4]. Prescribers should verify the legal status of compounded enclomiphene in their jurisdiction before writing a prescription for any patient, and especially before doing so for a minor.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism does not mention enclomiphene by name in the pediatric context, and the guideline explicitly recommends against testosterone therapy in boys with constitutional delay of puberty who do not have confirmed hypogonadism [5]. The same conservative logic applies to off-label SERM use.

Why No Validated Pediatric Dose Exists

The complete absence of a validated dosing protocol for children under 12 is not an oversight. It reflects three compounding problems.

First, no pediatric pharmacokinetic data exist. Adult dosing (12.5 to 25 mg daily) was derived from trials in men aged 18 to 60. Children have different hepatic cytochrome P450 activity, body composition, and protein-binding profiles. Allometric scaling from adult data is theoretically possible but has never been validated for enclomiphene.

Second, the mechanism of action raises specific developmental concerns. Enclomiphene blocks estrogen receptors at the hypothalamus and pituitary. In adult men, this disinhibits GnRH pulsatility and raises LH output. In a prepubertal child, the GnRH pulse generator is normally quiescent. Pharmacological disruption of hypothalamic estrogen signaling before the natural pubertal clock activates could theoretically accelerate bone age advancement, distort the normal sequence of pubertal hormone exposure, or suppress negative-feedback learning in the HPG axis. No study has tested whether these theoretical risks are real in humans under 12.

Third, the duration of effect is unknown in this age group. Zuclomiphene, the cis-isomer contaminant in racemic clomiphene, accumulates in fat tissue and has a half-life of weeks. Enclomiphene is pharmacokinetically cleaner, but long-term tissue accumulation data in growing children are entirely absent.

A practical decision framework for clinicians receiving a request for enclomiphene in a child under 12 should include four sequential checkpoints:

1. Confirm the diagnosis. Secondary (central) hypogonadism must be biochemically confirmed with at least two morning LH, FSH, and total testosterone measurements, plus GnRH stimulation testing if basal gonadotropins are low-normal.
2. Exhaust approved alternatives. Pulsatile GnRH pump therapy and gonadotropin injections (hCG with or without FSH) have published pediatric dosing data and are the standard of care for central hypogonadism in children [6].
3. Document failure or contraindication to standard therapy. Only after approved options have failed or are medically contraindicated should off-label SERM therapy be considered.
4. Obtain formal pediatric endocrinology and ethics consultation. For any child under 12, a second specialist opinion and, in most institutional settings, an ethics consultation should be documented before initiating off-label enclomiphene.

Enclomiphene vs. Clomiphene in Pediatric and Adolescent Literature

Clomiphene citrate (the racemic mixture containing both enclomiphene and zuclomiphene) has a longer off-label history in adolescent males than enclomiphene does. Small case series have described clomiphene use in adolescent boys aged 13 to 17 with constitutional delay of puberty or idiopathic hypogonadotropic hypogonadism, with doses of 25 to 50 mg daily or every other day. No randomized controlled trial of clomiphene in males under 12 exists in the PubMed literature.

Enclomiphene's theoretical advantage over clomiphene is the absence of zuclomiphene, which has partial estrogen-agonist activity and accumulates over time. This advantage is documented in adult men. Whether the reduced estrogen agonism of enclomiphene represents a meaningful safety improvement in children, versus racemic clomiphene, has never been tested in a trial.

A 2020 systematic review on medical management of hypogonadotropic hypogonadism in boys (Rohayem et al., Eur J Endocrinol) found sufficient evidence to support pulsatile GnRH and gonadotropin therapy for inducing puberty but noted that SERM evidence in this population was limited to small, uncontrolled series with short follow-up periods [6]. Enclomiphene was not individually addressed.

The American Academy of Pediatrics (AAP) has not published a position statement specifically on SERM therapy for prepubertal hypogonadism. The American Urological Association's 2018 guideline on male infertility acknowledges clomiphene as an option for idiopathic male factor infertility but restricts this to adult patients [7].

What the Only Relevant Adult Trial Tells Us (and Its Limits for Pediatrics)

Kim et al. (BJU Int 2016) remains the most frequently cited controlled study of enclomiphene in secondary hypogonadism [1]. The trial enrolled 71 men with morning testosterone below 300 ng/dL and BMI between 25 and 42 kg/m2, mean age approximately 38 years. Participants received enclomiphene 12.5 mg daily, enclomiphene 25 mg daily, or testosterone gel 1.62% (AndroGel). At 16 weeks, mean testosterone increased from approximately 247 ng/dL at baseline to 412 ng/dL in the 12.5 mg group and 500 ng/dL in the 25 mg group, compared to 558 ng/dL with testosterone gel. LH and FSH rose in enclomiphene groups and fell in the testosterone gel group, confirming axis preservation.

This study tells us that 12.5 mg once daily is the lower end of an effective adult dose and that the drug is well-tolerated over 16 weeks in men with established obesity and metabolic syndrome. It tells us nothing about dosing in a 7-year-old boy, a 10-year-old with Kallmann syndrome, or any other child under 12. The pharmacodynamic endpoints (LH rise, testosterone normalization) may not even be appropriate therapeutic targets in prepubertal children, where initiating full androgen exposure prematurely carries its own risks.

Extrapolating from a 38-year-old man with a BMI of 32 to a 25-kilogram child is not straightforward allometric scaling. Body surface area-based dosing would suggest a starting dose well below 6 mg daily, but this figure has no clinical validation.

Growth and Development Monitoring Considerations

If, after exhausting all approved options and completing the decision framework outlined above, a clinician and family decide to proceed with off-label enclomiphene in a child under 12, a minimum monitoring protocol should be in place.

Bone age X-ray (left hand and wrist, Greulich-Pyle method) at baseline and every 6 months is standard when any sex steroid or SERM is used in growing children. Testosterone accelerates bone maturation, and if enclomiphene raises testosterone levels, it could reduce adult height potential if bone age advances faster than chronological age.

Serum measurements should include total testosterone (Tanner-stage-specific reference ranges, not adult ranges), LH, FSH, and sex-hormone-binding globulin (SHBG) at baseline, 6 to 8 weeks after initiation, and every 3 months thereafter. A pre-pubertal testosterone target, if the goal is simply axis activation for puberty induction, is generally defined as progression into early Tanner stage 2 markers, not adult-range values.

The Endocrine Society's 2019 guideline on gender-dysphoria hormone therapy (not the same population, but the closest guideline to address puberty alteration in minors) explicitly requires bone age monitoring and growth velocity tracking every 6 months for any hormone-active compound used in children [8]. Applying that same standard to off-label enclomiphene use is a reasonable minimum.

Vision changes, a known side effect of clomiphene and theoretically possible with enclomiphene (given the shared SERM mechanism), should be monitored with a baseline ophthalmologic exam and parental instructions to report any visual symptoms immediately. The FDA's package insert for clomiphene citrate (Clomid) lists visual disturbances as grounds for immediate drug discontinuation [9].

Compounding, Formulation, and Dose Accuracy in Children

Children under 12 who might receive enclomiphene would almost certainly require a compounded liquid formulation or a low-dose capsule (below the 12.5 mg adult starting dose) because no commercially finished pediatric tablet exists. Compounding introduces dose uniformity concerns that do not exist with FDA-approved solid oral formulations.

The FDA's 2012 guidance on compounding quality and the subsequent Drug Quality and Security Act (DQSA) established oversight standards, but 503A compounding for individual patients is regulated primarily at the state board of pharmacy level [4]. A compounding pharmacy producing enclomiphene oral suspension for a child should be able to provide:

• Certificate of analysis confirming assay (dose accuracy) and absence of microbial contamination.
• Stability data for the specific vehicle (oral suspension) at room temperature and refrigerated conditions.
• Beyond-use dating consistent with USP Chapter 795 standards for non-sterile preparations.

Dose inaccuracy in a pediatric compounded formulation is not a trivial concern. A 10% overage in a 25 mg adult dose adds 2.5 mg, which may be inconsequential. The same 10% overage in a 5 mg pediatric dose is proportionally identical but may have a larger relative biological effect in a smaller child with different metabolic clearance.

Specialist Referral and Institutional Oversight

A general practitioner or family medicine physician should not initiate enclomiphene in a child under 12 without a formal evaluation and recommendation from a board-certified pediatric endocrinologist. The underlying diagnosis (central hypogonadism, constitutional delay, Prader-Willi syndrome, Kallmann syndrome) requires pituitary MRI to exclude structural lesions, genetic testing in appropriate cases, and a thorough differential that rules out primary testicular failure (which enclomiphene cannot treat).

"The approach to puberty delay in boys requires a systematic diagnostic workup before any hormonal intervention," states the Endocrine Society 2019 hypogonadism guideline. "Therapeutic options should be selected based on the underlying etiology and the patient's developmental stage" [5].

Telemedicine platforms, including those prescribing compounded enclomiphene to adult men for secondary hypogonadism, should have explicit policies against prescribing this drug to patients under 18 without specialist documentation. For patients under 12, the bar should be higher still.

Summary of the Evidence Gap and Clinical Bottom Line

The evidence gap for enclomiphene in children under 12 is complete. No phase 1 pharmacokinetic study, no randomized trial, no validated dosing protocol, and no regulatory guidance exists for this age group. The only controlled trial supporting enclomiphene use at any dose enrolled adult men with a mean age of 38 [1]. Approved and evidence-supported treatments for central hypogonadism in boys, including pulsatile GnRH therapy and hCG-based gonadotropin protocols, should be tried first [6].

Any off-label use of enclomiphene in a child under 12 requires:

• Board-certified pediatric endocrinology consultation with documented rationale.
• Biochemically confirmed secondary hypogonadism.
• Documented failure of or contraindication to approved therapies.
• Baseline and interval bone age X-rays every 6 months.
• Serum testosterone, LH, and FSH monitoring every 3 months.
• Compounding pharmacy certificate of analysis for each dispensed lot.
• A written informed consent/assent document that explicitly states the off-label nature of the treatment, the absence of pediatric clinical trial data, and the theoretical risks to growth and HPG axis development.